Detalhe da pesquisa
1.
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Lancet
; 399(10341): 2113-2128, 2022 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644166
2.
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.
Gastroenterology
; 162(7): 1891-1910, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35227777
3.
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.
Antimicrob Agents Chemother
; 62(10)2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30061289
4.
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
Antimicrob Agents Chemother
; 62(2)2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29180522
5.
An interferon-free antiviral regimen for HCV after liver transplantation.
N Engl J Med
; 371(25): 2375-82, 2014 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25386767
6.
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
N Engl J Med
; 370(3): 222-32, 2014 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-24428468
7.
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
N Engl J Med
; 370(21): 1983-92, 2014 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-24795200
8.
Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study.
Clin Infect Dis
; 60(4): 608-10, 2015 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25365973
9.
Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir.
Antimicrob Agents Chemother
; 59(9): 5445-54, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26100711
10.
In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.
Antimicrob Agents Chemother
; 59(2): 979-87, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25451055
11.
Posterior predictive Bayesian phylogenetic model selection.
Syst Biol
; 63(3): 309-21, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24193892
12.
Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lancet Gastroenterol Hepatol
; 9(3): 238-250, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38211604
13.
Improving marginal likelihood estimation for Bayesian phylogenetic model selection.
Syst Biol
; 60(2): 150-60, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21187451
14.
Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis.
J Crohns Colitis
; 15(12): 2022-2030, 2021 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34107013
15.
Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.
PLoS One
; 13(10): e0205186, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30286205
16.
Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
J Gastroenterol
; 53(5): 689, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29134328
17.
Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
J Gastroenterol
; 53(4): 566-575, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29052790
18.
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
J Gastroenterol
; 53(4): 557-565, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28948366
19.
Dose-ranging design and analysis methods to identify the minimum effective dose (MED).
Contemp Clin Trials
; 63: 59-66, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28818433
20.
A Bayesian Approach to Pathway Analysis by Integrating Gene-Gene Functional Directions and Microarray Data.
Stat Biosci
; 4(1): 105-131, 2012 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23482678